These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26923902)

  • 41. Small molecule modulators of histone acetylation and methylation: a disease perspective.
    Selvi BR; Mohankrishna DV; Ostwal YB; Kundu TK
    Biochim Biophys Acta; 2010; 1799(10-12):810-28. PubMed ID: 20888936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging approaches for histone deacetylase inhibitor drug discovery.
    Zwergel C; Valente S; Jacob C; Mai A
    Expert Opin Drug Discov; 2015 Jun; 10(6):599-613. PubMed ID: 25895649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
    Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
    Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.
    Lunke S; El-Osta A
    J Neurochem; 2009 Jun; 109(6):1557-69. PubMed ID: 19383090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
    Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
    Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histone deacetylases: Targets for antifungal drug development.
    Kmetzsch L
    Virulence; 2015; 6(6):535-6. PubMed ID: 26151486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells.
    Singh B; Boopathy S; Somasundaram K; Umapathy S
    J Biophotonics; 2012 Mar; 5(3):230-9. PubMed ID: 22259119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential.
    Vu LP; Luciani L; Nimer SD
    Int J Hematol; 2013 Feb; 97(2):198-209. PubMed ID: 23288492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diverse Activities of Histone Acylations Connect Metabolism to Chromatin Function.
    Dutta A; Abmayr SM; Workman JL
    Mol Cell; 2016 Aug; 63(4):547-552. PubMed ID: 27540855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent progress in developing selective inhibitors of protein methyltransferases.
    Kaniskan HÜ; Jin J
    Curr Opin Chem Biol; 2017 Aug; 39():100-108. PubMed ID: 28662389
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Challenges in profiling and lead optimization of drug discovery for methyltransferases.
    Horiuchi KY
    Drug Discov Today Technol; 2015 Nov; 18():62-8. PubMed ID: 26723894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chromatin control and cancer-drug discovery: realizing the promise.
    Inche AG; La Thangue NB
    Drug Discov Today; 2006 Feb; 11(3-4):97-109. PubMed ID: 16533707
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How could histone deacetylase activators be useful leads in the search for new therapeutics?
    Bourguet E; Naassila M
    Future Med Chem; 2019 Jun; 11(11):1241-1243. PubMed ID: 31161790
    [No Abstract]   [Full Text] [Related]  

  • 55. HDAC4 Inhibitors as Antivascular Senescence Therapeutics.
    Huang C; Lin Z; Liu X; Ding Q; Cai J; Zhang Z; Rose P; Zhu YZ
    Oxid Med Cell Longev; 2022; 2022():3087916. PubMed ID: 35814270
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.
    Scheer S; Ackloo S; Medina TS; Schapira M; Li F; Ward JA; Lewis AM; Northrop JP; Richardson PL; Kaniskan HÜ; Shen Y; Liu J; Smil D; McLeod D; Zepeda-Velazquez CA; Luo M; Jin J; Barsyte-Lovejoy D; Huber KVM; De Carvalho DD; Vedadi M; Zaph C; Brown PJ; Arrowsmith CH
    Nat Commun; 2019 Jan; 10(1):19. PubMed ID: 30604761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Wellcome Trust Award Lecture. Chromatin-modifying enzymes in transcription and cancer.
    Kouzarides T
    Biochem Soc Trans; 2003 Aug; 31(Pt 4):741-3. PubMed ID: 12887294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histones and heart failure in diabetes.
    Yerra VG; Advani A
    Cell Mol Life Sci; 2018 Sep; 75(17):3193-3213. PubMed ID: 29934664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic mechanisms governing the process of neurodegeneration.
    Qureshi IA; Mehler MF
    Mol Aspects Med; 2013; 34(4):875-82. PubMed ID: 22782013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HISTome2: a database of histone proteins, modifiers for multiple organisms and epidrugs.
    Shah SG; Mandloi T; Kunte P; Natu A; Rashid M; Reddy D; Gadewal N; Gupta S
    Epigenetics Chromatin; 2020 Aug; 13(1):31. PubMed ID: 32746900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.